BIoPharm releases upcoming training schedule for Oracle Life Science Courses-new course alert.
At BioPharm Systems' training facility in San Mateo, California Course Dates/Brochures/Price per student
Jun 9–11/Oracle TMS Basics/$1,500
Jun 12–13/Oracle TMS Advanced/$1,000
Jun 16–18/Oracle AERS Basic/$1,500
Jun 19–20/Oracle AERS Administration/$1,000
Jun 16–20/Oracle Clinical Basic/$2,000
Aug 12–13/RDC for Sponsors 4.5.3/$1,000
We have several ways to register for courses: through our registration form, on our Web site (www.biopharm.com) using Google Checkout or contact us either telephone at (650) 292-5301 or email.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.